Soleno Therapeutics (NASDAQ:SLNO) Lowered to Hold Rating by Robert W. Baird

Robert W. Baird lowered shares of Soleno Therapeutics (NASDAQ:SLNO) from a strong-buy rating to a hold rating in a research note released on Monday morning,Zacks.com reports.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Wolfe Research lowered shares of Soleno Therapeutics from an “outperform” rating to a “hold” rating in a research note on Tuesday. Wells Fargo & Company lowered their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. HC Wainwright lowered their price objective on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, March 4th. Finally, Cantor Fitzgerald lowered shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $123.00 to $53.00 in a research note on Monday. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $93.90.

Soleno Therapeutics Stock Performance

NASDAQ:SLNO opened at $52.35 on Monday. The company has a fifty day moving average of $38.17 and a 200-day moving average of $47.80. The firm has a market capitalization of $2.70 billion, a P/E ratio of 227.62 and a beta of -2.81. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics has a twelve month low of $29.43 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. As a group, sell-side analysts anticipate that Soleno Therapeutics will post -3.72 EPS for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently bought and sold shares of SLNO. Raymond James Financial Inc. purchased a new position in Soleno Therapeutics during the 2nd quarter worth $25,000. Danske Bank A S purchased a new position in Soleno Therapeutics during the 3rd quarter worth $27,000. Global Retirement Partners LLC boosted its holdings in Soleno Therapeutics by 519.0% during the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after acquiring an additional 519 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Soleno Therapeutics during the 3rd quarter worth $37,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Soleno Therapeutics during the 4th quarter worth $38,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for about $2.9B, offering $53.00 per share in cash (a meaningful premium to recent trade); the deal provides a near‑term liquidity event and floor for shareholder value. Neurocrine to Buy Soleno for $2.9 Billion
• Positive Sentiment: Market commentary and coverage noted the $53/share offer and framed it as a strategic fit for Neurocrine’s rare‑disease/endocrinology push, supporting near‑term upside to the transaction price if the deal closes. Neurocrine Biosciences to acquire Soleno Therapeutics
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for its Prader‑Willi treatment as Neurocrine sharpens focus on the U.S. market — a programmatic change that reduces near‑term EU regulatory exposure but removes a potential international revenue opportunity. Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
• Negative Sentiment: Several sell‑side firms downgraded or cut price targets (Cantor Fitzgerald, Wolfe Research, Lifesci; TD Cowen cut its target to $53 from $85) — analyst caution could pressure sentiment and constrain upside beyond the deal price. Cantor Fitzgerald Downgrades Soleno Therapeutics
• Negative Sentiment: Multiple securities class‑action lawsuits, and a flurry of law‑firm notices seeking lead plaintiffs, allege disclosures issues tied to the DCCR (VYKAT XR) program; several firms are investigating the fairness of the Neurocrine deal and potential fiduciary claims — these legal risks can create deal uncertainty, potential remediation costs, and timeline delays. Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit
• Negative Sentiment: Investor‑rights and M&A litigation firms have launched investigations into whether Soleno’s board obtained a fair price and whether prior disclosures misstated drug risks — these actions raise the chance of post‑deal litigation or negotiated adjustments. Halper Sadeh investigation into sale price

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.